Sept. 5, 2003 — Caregivers of children treated with once or twice daily budesonide reported fewer limitations in daily activities and emotional functioning than caregivers of children treated with ...

Purpose: To evaluate the effectiveness of budesonide inhalation suspension relative to other common asthma therapies in a high-risk population, a study was conducted to compare the risk of having a ...

JERUSALEM--(BUSINESS WIRE)--Mar. 9, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the launch of the generic equivalent to Pulmicort Respules®1 (budesonide inhalation ...

Daily inhaled glucocorticoids are recommended for young children at risk for asthma exacerbations, as indicated by a positive value on the modified asthma predictive index (API) and an exacerbation in ...

Short-term budesonide transnasal nebulization effectively and safely treated patients with chronic rhinosinusitis with nasal polyps when compared with placebo, according to study results. In a double ...

Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, announced the launch of the generic equivalent to Pulmicort Respules (budesonide inhalation suspension), 1 mg/2 ml, in the ...

Aurobindo Pharma’s wholly-owned subsidiary company, Eugia Pharma Specialities Ltd, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Budesonide ...

"The global budesonide inhaler market is set for robust growth as increasing respiratory disorders and the expansion of generic alternatives drive demand for affordable, effective inhalation therapies ...

AstraZeneca today announced that the United States District Court for the District of New Jersey ruled that AstraZeneca's US Patent No. 6,598,603 ("the '603 patent"), protecting PULMICORT RESPULES in ...